HeartSciences Sets Nov 19 Vote on Fortitude Merger; Legacy Holders Left With ~6%
HSCS sits 89% above its 52-week low of $1.63.
Summary
HeartSciences filed the definitive proxy for its all-stock merger with DCG's Fortitude Mining, with a November 19, 2026 shareholder vote. Existing holders would keep only about 6% of the combined company, and the proxy also seeks authority for up to 35 million additional Class A shares post-closing.
Key Events · M&A and Partnerships · HSCS
-
Definitive Proxy Filed, Vote Set
A special meeting is scheduled for November 19, 2026 to approve the merger with Fortitude Mining Holdings, a DCG subsidiary, along with Nasdaq, charter, reverse split and equity plan proposals.
-
Legacy Holders Cut to ~6%
Post-closing, Fortitude Seller is expected to hold about 94% of voting interests via Class V and Class A stock; existing HeartSciences equityholders keep roughly 6% (about 6.8 million Class A shares of 7.68 million total Class A).
-
Up to 35M More Shares Authorized
Proposal 2 permits issuance of up to 35,000,000 Class A shares within one month of closing for up to $100 million in cash, Zcash or debt satisfaction, at a maximum 20% discount to market.
-
Nasdaq Compliance Extended to Feb 1, 2027
Nasdaq accepted the company's compliance plan on October 15, 2026, giving until February 1, 2027 to cure the stockholders' equity deficiency, with the merger as the stated remedy.
Analysis · HSCS · Crypto Assets
The definitive proxy now puts the Fortitude Mining reverse merger to a binding shareholder vote on November 19, 2026. The economics are stark: legacy HeartSciences holders end up with roughly 6% of the combined company, while DCG's Fortitude Seller holds about 94% of voting power through non-economic Class V stock. The proxy also asks for authority to issue up to 35 million more Class A shares (up to $100M) within a month of closing. For a company that reported $29,906 of cash and negative $2.03 million of equity in its September 10-Q, the deal is effectively the survival path. The board states that without it HeartSciences has limited ability to continue operations and may have to liquidate, with no assurance any cash would reach shareholders. Approval is largely pre-wired: holders of more than 50% of the Series C preferred have signed support agreements, and the vote requires a majority of outstanding shares, so a low retail turnout works in favor of passage. The main open condition is Nasdaq confirming the Class A listing, which is why the reverse split (1-for-2 to 1-for-5) is on the ballot to clear the $4.00 minimum bid price.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HSCS was trading at $3.08 on NASDAQ in the Crypto Assets sector, with a market capitalization of approximately $14.6M. The 52-week trading range was $1.63 to $5.25. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.